[Effect of 2-ethyl-6-methyl-3-oxypyridine on the sympathetic-adrenal system of tumor carriers].
D000311:Adrenal Glands / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000188:drug therapy* / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D008297:Male; D009368:Neoplasm Transplantation; D010847:Picolines / Q000627:therapeutic use*; D051381:Rats; D013564:Sympathetic Nervous System / Q000187:drug effects*; D013997:Time Factors
D000975:Antioxidants; D002395:Catecholamines; D010847:Picolines; D003520:Cyclophosphamide; C009820:6-methyl-2-ethyl-3-hydroxypyridine
Vliianie 2-étil-6-metil-3-oksipiridina na simpato-adrenalovuiu sistemu opukholenositeleĭ.